CY1107620T1 - Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis - Google Patents
Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalisInfo
- Publication number
- CY1107620T1 CY1107620T1 CY20071100548T CY071100548T CY1107620T1 CY 1107620 T1 CY1107620 T1 CY 1107620T1 CY 20071100548 T CY20071100548 T CY 20071100548T CY 071100548 T CY071100548 T CY 071100548T CY 1107620 T1 CY1107620 T1 CY 1107620T1
- Authority
- CY
- Cyprus
- Prior art keywords
- moraxella catarrhalis
- haemophilus influenzae
- component
- antigens
- protection against
- Prior art date
Links
- 241000606768 Haemophilus influenzae Species 0.000 title abstract 4
- 241000588655 Moraxella catarrhalis Species 0.000 title abstract 4
- 229940047650 haemophilus influenzae Drugs 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 241000991587 Enterovirus C Species 0.000 abstract 1
- 241000606790 Haemophilus Species 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000002293 adipogenic effect Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 229940124856 vaccine component Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Μία πολυ-σθενής ανοσογόνος σύνθεση που αποφέρει προστασία σε έναν ανοσοποιημένο ξενιστή έναντι της λοίμωξης που προκαλείται από αμφότερα τον Haemophilus influenzae και την Moraxella catarrhalis. Η σύνθεση αυτού του είδους περιλαμβάνει τέσσερα τουλάχιστον αντιγόνα περιλαμβάνοντας ένα τουλάχιστον αντιγόνο από τον Haemophilus influenzae, και ένα τουλάχιστον αντιγόνο από την Moraxella catarrhalis. Τρία από τα αντιγόνα είναι προσκολλητίνες. Οι πρωτεΐνες υψηλού μοριακού βάρους (HMW) και οι πρωτεΐνες προσκολλητίνης του Haemophilus influenzae (Hia) του μη-τυποποιήσιμου Haemophilus και μία πρωτεΐνη εξωτερικής μεμβράνης των 200 kDa της Moraxella catarrhalis περιλαμβάνουν τα συστατικά προσκολλητίνης, ενώ το άλλο αντιγόνο είναι ένα μη-πρωτεολυτικό ανάλογο της πρωτεΐνης Hin47. Το κάθε ένα συστατικό δεν μειώνει την ανοσογονικότητα των άλλων. Η πολυ-ασθενής ανοσογόνος σύνθεση μπορεί να συνδυαστεί με εμβόλια συστατικού DTP, η οποία μπορεί επίσης να συμπεριλαμβάνει μη-μολυσματικό πολυοϊό και PRP-T για την παροχή ενός συστατικού εμβολίου χωρίς εξασθένιση των ανοσογόνων ιδιοτήτων των άλλων αντιγόνων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/353,617 US6391313B1 (en) | 1999-07-15 | 1999-07-15 | Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis |
EP00945494A EP1200122B1 (en) | 1999-07-15 | 2000-07-11 | Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107620T1 true CY1107620T1 (el) | 2013-03-13 |
Family
ID=23389874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100548T CY1107620T1 (el) | 1999-07-15 | 2007-04-23 | Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis |
Country Status (12)
Country | Link |
---|---|
US (1) | US6391313B1 (el) |
EP (2) | EP1200122B1 (el) |
AT (1) | ATE353223T1 (el) |
AU (1) | AU767096B2 (el) |
CA (1) | CA2378862C (el) |
CY (1) | CY1107620T1 (el) |
DE (1) | DE60033291T2 (el) |
DK (1) | DK1200122T3 (el) |
ES (1) | ES2280230T3 (el) |
PT (1) | PT1200122E (el) |
SI (1) | SI1200122T1 (el) |
WO (1) | WO2001005424A2 (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
EP1203082A1 (en) * | 1999-07-27 | 2002-05-08 | Aventis Pasteur Limited | Recombinant high molecular weight major outer membrane protein of moraxella |
SE0102410D0 (sv) * | 2001-07-04 | 2001-07-04 | Arne Forsgren | Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis |
US8415361B2 (en) | 2007-11-09 | 2013-04-09 | The Salk Institute For Biological Studies | Use of TAM receptor inhibitors as antimicrobials |
CN105175549B (zh) * | 2015-09-30 | 2019-08-16 | 康希诺生物股份公司 | 一种流感嗜血杆菌融合蛋白及其构建方法与应用 |
WO2018178265A1 (en) * | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
WO2018178264A1 (en) * | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496538A (en) | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
KR100188323B1 (ko) * | 1989-03-09 | 1999-06-01 | 이곤 이이 버어그 | 비타입성 헤모필루스 인플렌자에 대한 백신 |
US5843463A (en) | 1990-12-21 | 1998-12-01 | Antexbiologics, Inc. | Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae |
US5603938A (en) | 1992-03-16 | 1997-02-18 | St. Louis University | High molecular weight surface proteins of non-typeable haemophilus |
US5977336A (en) | 1993-03-16 | 1999-11-02 | St. Louis University | High molecular weight surface proteins of non-typeable haemophilus |
EP0689453A4 (en) * | 1993-03-16 | 1996-03-13 | Stephen J Barenkamp | A SURFACE PROTEIN WITH A HIGH MOLECULAR MEASUREMENT OF THE NON-TYPICAL HEMOPHILUS |
US5712118A (en) * | 1993-09-29 | 1998-01-27 | Research Foundation Of State University Of New York | Vaccine for branhamella catarrhalis |
US5506139A (en) | 1994-07-21 | 1996-04-09 | Connaught Laboratories Limited | Analog of haemophilus Hin47 with reduced protease activity |
US6764682B1 (en) | 1994-06-16 | 2004-07-20 | Aventis Pasteur Limited | Adjuvant compositions containing more than one adjuvant |
BR9506272B8 (pt) | 1994-07-21 | 2014-08-05 | Connaught Lab | PROTEÍNA MUTANTE ISOLADA E PURIFICADA Hin47 DE Haemophilus influenzae, MOLÉCULA QUIMÉRICA, MOLÉCULA DE ÁCIDO NUCLÉICO, PLASMÍDEO RECOMBINANTE, CÉLULA E. coli TRANSFORMADA, COMPOSIÇÃO IMUNOGÊNICA, PROCESSO PARA DETERMINAR A PRESENÇA DE ANTICORPOS, ESPECIFICAMENTE REATIVOS COM A PROTEÍNA Hin47 NUMA AMOSTRA, PROCESSO PARA DETERMINAR A PRESENÇA DE PROTEÍNA Hin47 NUMA AMOSTRA E KIT DE DIAGNÓSTICO PARA DETERMINAR A PRESENÇA DE ANTICORPOS NUMA AMOSTRA ESPECIFICAMENTE REATIVA COM A PROTEÍNA Hin47. |
US5646259A (en) | 1995-03-24 | 1997-07-08 | St. Louis University | DNA encoding haemophilus adhesion proteins |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US6335018B1 (en) | 1995-05-01 | 2002-01-01 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
CA2315746A1 (en) * | 1998-01-13 | 1999-07-22 | The Government Of The United States Of America | Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals |
US6974581B1 (en) * | 1998-12-15 | 2005-12-13 | Aventis Pasteur Limited | Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease |
-
1999
- 1999-07-15 US US09/353,617 patent/US6391313B1/en not_active Expired - Lifetime
-
2000
- 2000-07-11 DE DE60033291T patent/DE60033291T2/de not_active Expired - Lifetime
- 2000-07-11 PT PT00945494T patent/PT1200122E/pt unknown
- 2000-07-11 AU AU59586/00A patent/AU767096B2/en not_active Ceased
- 2000-07-11 AT AT00945494T patent/ATE353223T1/de active
- 2000-07-11 SI SI200030936T patent/SI1200122T1/sl unknown
- 2000-07-11 CA CA002378862A patent/CA2378862C/en not_active Expired - Fee Related
- 2000-07-11 ES ES00945494T patent/ES2280230T3/es not_active Expired - Lifetime
- 2000-07-11 EP EP00945494A patent/EP1200122B1/en not_active Revoked
- 2000-07-11 WO PCT/CA2000/000811 patent/WO2001005424A2/en active IP Right Grant
- 2000-07-11 EP EP06076726A patent/EP1880734A3/en not_active Withdrawn
- 2000-07-11 DK DK00945494T patent/DK1200122T3/da active
-
2007
- 2007-04-23 CY CY20071100548T patent/CY1107620T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1200122B1 (en) | 2007-02-07 |
CA2378862C (en) | 2005-05-10 |
DE60033291T2 (de) | 2007-07-05 |
DE60033291D1 (de) | 2007-03-22 |
SI1200122T1 (sl) | 2007-08-31 |
EP1200122A2 (en) | 2002-05-02 |
ATE353223T1 (de) | 2007-02-15 |
AU5958600A (en) | 2001-02-05 |
PT1200122E (pt) | 2007-05-31 |
WO2001005424A2 (en) | 2001-01-25 |
ES2280230T3 (es) | 2007-09-16 |
EP1880734A3 (en) | 2008-06-25 |
EP1880734A2 (en) | 2008-01-23 |
WO2001005424A3 (en) | 2001-08-02 |
AU767096B2 (en) | 2003-10-30 |
DK1200122T3 (da) | 2007-06-04 |
US6391313B1 (en) | 2002-05-21 |
CA2378862A1 (en) | 2001-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107620T1 (el) | Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis | |
CY1110359T1 (el) | Εμβολια με βαση σιρκοϊους χοιρων | |
WO2008026225A3 (en) | A vaccine for chikungunya virus infection | |
CY1114333T1 (el) | Αντιγονα του neisseria meningitidis | |
CY1115842T1 (el) | Συμπληρωμενο ομv εμβολιο κατα μηνιγγιtiδοκοκκου | |
NO20075902L (no) | Forbindelser for immunoterapi og diagnose av turberkolose og metoder for deres anvendelse | |
NO20050396L (no) | Adjuvant viral partikkel | |
CY1105010T1 (el) | Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου | |
WO1998046725A3 (en) | Attenuated, invasive vaccines against fish pathogens | |
CY1106252T1 (el) | Εμβολιο πολλαπλων συστατικων που πepιλαμβανει τουλαχιστον δυο αντιγονα απο haemophilus influenzae για την προστασια εναντι νοσησης | |
ATE310014T1 (de) | Hepatitis b-impfstoff | |
ATE101200T1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
BR9704879A (pt) | Composição de vacina e uso de um vírus cav vivo | |
DE68915046D1 (de) | Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff. | |
HUP9904171A2 (hu) | A ragadós száj- és körömfájás vírusok immunogén peptidjei | |
WO2002009749A3 (en) | Respiratory syncytial virus vaccine | |
DE69922212D1 (de) | Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp) | |
SE9903534D0 (sv) | Vaccin | |
BR9709993A (pt) | Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica | |
AU6435596A (en) | Pasteurella haemolytica type A-1 bacterin-toxoid vaccine | |
FR2724385B1 (fr) | Vaccin de la peritonite infectieuse feline. | |
DE69433760D1 (de) | Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält | |
PL331792A1 (en) | Aviadenovirus, nucleic acid sequence encoding an antigen determinant, host cell transformed by such sequence, antibody or immune serum reacting with such antigen determinant and vaccine against diseases associated with a novel adenovirus | |
DE69228063D1 (de) | Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1 |